Phenylephrine hydrochloride (HCl) is a decongestant available in over-the-counter (OTC) medicines. Previously marketed prescription products contained phenylephrine tannate, an extended-release salt, which allowed dosing every 8-12 h. Given the regulatory history that cold medicines marketed before 1962 had limited supporting clinical data, and with widespread replacement of pseudoephedrine by phenylephrine in OTC products over the last ten years, the need for contemporary studies grew. This exploratory crossover study evaluated effects of salt form, acetaminophen, and food on phenylephrine pharmacokinetics and metabolites in healthy adults. Test treatments were 25 mg phenylephrine tannate (equivalent to 10 mg phenylephrine HCl) combined with 200 mg guaifenesin, fasted; 10 mg phenylephrine HCl combined with 650 mg acetaminophen, fasted; and 10 mg phenylephrine HCl, fed. The reference treatment was 10 mg phenylephrine HCl, fasted. Plasma phenylephrine pharmacokinetics and urine metabolites were determined. Although the tannate salt slowed phenylephrine absorption compared with the HCl salt, terminal concentrations were similar, suggesting that products containing the tannate salt should not be dosed less frequently than those containing the HCl salt. The premise that acetaminophen increases phenylephrine bioavailability by competition for presystemic sulfation was corroborated by increased phenylephrine sulfate in urine. Food delayed phenylephrine absorption, but not the total amount absorbed.
Introduction
Phenylephrine hydrochloride (HCl) is a nasal decongestant used in single-and multiple-ingredient over-the-counter (OTC) medicines and is indicated for the temporary relief of nasal congestion caused by the common cold or allergies. In the United States (US), the adult dosage is 10 mg every 4 h with a total allowable daily dose of 60 mg. Phenylephrine HCl has been available prior to the 1960's before the advent of rigorous clinical development. It was studied in several placebo-controlled, crossover clinical trials that were reviewed by an expert panel and provided the basis for phenylephrine HCl and bitartrate salts being generally recognized as safe and effective in the US OTC drug monograph for Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products in 21 Code of Federal Regulations (CFR) Part 341 (FDA, 1994) .
Phenylephrine's use in commercial OTC drug products was insubstantial compared with pseudoephedrine, the longer-acting nasal decongestant, until 2006. Illicit use of pseudoephedrine as a precursor in the synthesis of methamphetamine had grown significantly, which prompted the US Congress to enact the Combat Methamphetamine Epidemic Act that limits the sale of products containing pseudoephedrine to behind-the-counter placement in pharmacies and the amount sold to each customer (CDC, 2013) . To expand consumer access to OTC cold products beyond pharmacies, manufacturers replaced pseudoephedrine sulfate with phenylephrine HCl in many products.
With the transition to phenylephrine-containing OTC cold products, lack of contemporary clinical pharmacology data created the need to study phenylephrine, beginning with the development of a sensitive, validated assay for plasma concentrations (Ptacek and Macek, 2007) . Subsequent studies identified a pharmacokinetic drug-drug interaction between the analgesic, acetaminophen, and phenylephrine (Atkinson et al., 2014 (Atkinson et al., , 2015a , and evaluated the pharmacokinetics, metabolism, and cardiovascular tolerability of 10, 20, and 30 mg phenylephrine HCl (Gelotte and Zimmerman, 2015) . Collectively these published studies, along with an early study on radio-labeled phenylephrine (Hengstmann and Goronzy, 1982) , found that phenylephrine is rapidly absorbed after oral administration, ranging from 20 to 75 min, and has a short terminal exponential half-life, ranging from 0.5 to 2.5 h, and low bioavailability (38%) due to high first-pass metabolism. For the 10-mg phenylephrine HCl dose, mean total exposure (AUC∞) ranged from 956 to 1916 pg h/mL across studies and mean maximum exposure (CMAX) ranged from 874 to 1600 pg/mL. The high degree of intersubject variability noted in these exposure parameters is characteristic of drugs that undergo high first-pass metabolism. The large study-to-study differences may reflect differences in the plasma assays or study populations.
Phenylephrine tannate, a reportedly extended-release salt form of phenylephrine, was formulated in prescription cold and allergy products that allowed dosing every 8-12 h. A 25-mg dose of phenylephrine tannate contains approximately the same amount of free base phenylephrine (∼8 mg) as the 10-mg dose of phenylephrine HCl. At the time of this study, phenylephrine tannate was on the list of unapproved drugs pending review under the Drug Efficacy Study Implementation program, which classified pre-1962 drugs that were already on the market as either effective, ineffective, or needing further study (Guidance for FDA Staff and Industry, 2011) .
The objective of this exploratory study was to learn more about the clinical pharmacology of phenylephrine, specifically whether the tannate salt is absorbed at a slower rate than the hydrochloride salt; whether acetaminophen alters the metabolism of phenylephrine, which would impact pharmacokinetics; and whether a high-fat meal affects phenylephrine bioavailability.
Methods

Ethics and study design
The study was conducted at a phase 1 clinic (Cetero Research, Fargo, ND) between March and May 2008 in compliance with the International Conference on Harmonization: Good Clinical Practice and the Health Insurance Portability and Accountability Act. The protocol and informed consent form were reviewed and approved by the PRACS Institutional Review Board (Fargo, ND). All subjects were informed of the nature and purpose of the study and gave written informed consent before screening.
The study had an open-label, randomized, four-treatment, crossover design to evaluate the effects of salt form, acetaminophen, and food on single-dose pharmacokinetics of phenylephrine in 20 healthy adults. Subjects were admitted to the clinic the evening before each treatment period and remained on site until after the last blood and urine samples were collected 24 h after dosing. Given the short half-life of phenylephrine, the periods were separated by at least a 3-day washout after a dose. Site personnel administered study drug following a four-treatment sequence randomization. During these treatments, subjects abstained from caffeine-containing products for 24 h before the study start until discharge. Standardized beverages and meals were free from grapefruit and xanthine containing products.
Subjects
Men and women ages 18 through 58 years with a body mass index approximately 18-29 kg/m 2 and a total body weight > 50 kg (110 lb) were eligible to participate if they were deemed healthy by medical history, physical examination, clinical laboratory profile (blood chemistry profile, hematology, urinalysis), vital signs, and 12-lead electrocardiogram (ECG). Prospective nonsmoking subjects were excluded if they had a history of clinically significant systemic conditions; hepatitis B or C, or antibodies to human immunodeficiency virus; taken any prescription or nonprescription medications or monoamine oxidase inhibitors within 7 days or 5 half-lives (whichever is longer) before dose administration; a history of excessive alcohol use; a positive urine drug screen; or a known sensitivity or allergy to phenylephrine. Women who were pregnant or nursing were excluded.
Treatments and investigational products
Commercially available drug products were supplied to the clinic in their original packages. For Treatments A, B, and D, subjects were administered the dose with 250 mL water after fasting overnight for at least 10 h and remained fasted until 4 h after dosing. These three fasting treatments were A: single dose of 25 mg phenylephrine tannate (equivalent to phenylephrine HCl 10 mg) administered as one combination tablet of SINA-12X
® ( 
Pharmacokinetics
Sample collection and assays
Fifteen blood samples (5 mL) for the pharmacokinetic evaluation of phenylephrine in each treatment were collected by direct venipuncture into tubes containing tripotassium ethylenediamine tetra-acetic acid as the anticoagulant. Because Treatment A included the long-acting tannate salt of phenylephrine and Treatment C would access potential food effects, blood sampling times were scheduled up to 8 h after each dose at predose; 10, 20, 30, 45, and 60 min; and 1.5, 2, 2.5, 3, 3.5, 4, 5, 6 and 8 h. Based on previous studies of phenylephrine HCl being rapidly absorbed and eliminated, blood collections were adjusted to earlier times for Treatments B and D at predose; 5, 10, 15, 20, 30, 35, 45, 50 , and 60 min; and 1.5, 2, 3, 4, and 5 h. Plasma was harvested from the blood samples and stored frozen at −70°C until assayed.
For the urine metabolite evaluation, subjects completely voided their bladders within 20 min of dosing for each treatment period, and a predose aliquot of urine was collected from this volume. All urine was collected throughout 24 h beginning immediately after the dose was administered and ending with the final, scheduled void. For each 24-h interval, urine was pooled into a covered container and stored refrigerated. The total amount collected was measured by weight and, after thorough mixing, aliquots were transferred and frozen at −70°C until assayed.
Bioanalytical assays were conducted by PPD, Inc. (Madison, WI). Plasma samples were analyzed for phenylephrine (unconjugated, free base) using a commercial, validated liquid chromatography-tandem spectrometry (LC/MS/MS) method with quantification limits from 10.0 to 2500 pg/mL (PPD Bioanalytical Laboratory, 2007) . The interassay accuracy ranged from 2.68% to 13.0%, and interassay variability ranged from 4.01 to 26.0% for quality control samples run during sample analysis.
Urine samples were analyzed for phenylephrine (unconjugated, free base), total phenylephrine (unconjugated plus enzyme-digested conjugates), phenylephrine-glucuronide, and 3-hydroxymandelic acid (3-HMA) using commercial, validated LS/MS/MS methods (PPD Bioanalytical Laboratory, 2008a; PPD Bioanalytical Laboratory, 2008b; PPD Bioanalytical Laboratory, 2008c) . The quantification limits were 2.0-200 ng/mL for phenylephrine and phenylephrine-glucuronide, and 100-5000 ng/mL for total phenylephrine and 3-HMA. The interassay precision and accuracy of quality control samples were < 13.6% and < 5.27%, respectively, for phenylephrine; < 15.7% and < 7.02%, respectively, for phenylephrine-glucuronide; < 3.41% and < 1.29%, respectively, for total phenylephrine; and < 12.0% and < 4.42%, respectively, for 3-HMA.
Pharmacokinetic and statistical analysis
No specific sample size calculation was applied, as this study was exploratory. A sample size of 20 subjects was considered sufficient to describe phenylephrine pharmacokinetics and metabolism adequately. Phenylephrine pharmacokinetic parameters were derived or observed from individual plasma concentration-time data and included maximum concentration (CMAX), time to maximum concentration (TMAX), area under the plasma concentration-time curve extrapolated to infinity (AUC∞), and terminal exponential half-life (t ½ ). Data were analyzed with actual sampling times using WinNonlin ® Version 5.2.1 (PharSight, Mountain View, CA) and noncompartmental methods (e.g., linear-log trapezoidal method for AUC). Concentrations below the lower limit of quantitation that occurred before and after CMAX were imputed as zero and missing, respectively. For the urine pharmacokinetic analysis, the total amounts of phenylephrine (unconjugated), total phenylephrine, and two metabolites (phenylephrine-glucuronide and 3-HMA) excreted in urine over 24 h were quantified. Because the sulfate metabolite could not be synthesized and assayed directly in urine, the amount excreted was estimated indirectly as described previously using the amount of total phenylephrine (Gelotte and Zimmerman, 2015) . The excreted amounts (Ax) were expressed as percentages of the administered phenylephrine dose (PDx), using the following equation: PDx (%) = [Ax (μmol)/(free-base dose (μmol)] x 100.
Statistical analyses were conducted using SAS ® , Version 9.2. (SAS Institute Inc., Cary, NC). Pharmacokinetic parameters were summarized with descriptive statistics, and natural logarithmic transformed AUC∞ and CMAX were analyzed using a mixed-effect analysis of variance (ANOVA). The general linear model procedure of SAS was used in the ANOVA for a four-treatment crossover design. Four factors in the ANOVA tested for effects of treatment, treatment sequence, subjects within sequence, and study period. The ratios of least-squares geometric means for phenylephrine AUC∞ and CMAX, comparing Treatments A, B, and C to Treatment D (reference), and associated 90% confidence intervals at α = 0.05 were determined.
Safety
For safety monitoring, vital signs were measured at screening, during each study period, and at the completion of the study. Safety was assessed by observed or spontaneously reported treatment-emergent adverse events throughout the study and review of vital signs (blood pressure and pulse measurements), laboratory values, and physical examinations.
Results and discussion
Twenty enrolled healthy adults (10 men and 10 women), ranging in age from 19 to 52 years, completed the study and were included in the pharmacokinetic and safety analyses. The study population had a mean body mass index of 24.8 ( ± 2.0) kg/m 2 , and included 1 Hispanic Black, 2 Native American, 1 Asian, and 16 White subjects. Mean plasma concentration-time profiles for phenylephrine are shown by treatment in Fig. 1 on the linear and semilogarithmic scales, and pharmacokinetic parameters are summarized in Table 1 . Fig. 2 shows the pharmacokinetic profiles for each pairwise comparison with the reference treatment, 10 mg phenylephrine HCl after fasting. Results from the statistical analysis comparing phenylephrine exposure parameters (AUC∞ and CMAX) for each combination product with the reference product after fasting are summarized in Table 2 along with results for the effect of food on phenylephrine absorption. Results from the urine analysis of phenylephrine and its metabolites are summarized by treatment in Table 3 .
Effect of salt form on phenylephrine pharmacokinetics
Tannic acid forms complexes or salts with drug molecules that have an amine group, producing tasteless substances with lower water solubility (Kaplan et al., 1963; Rahman et al., 2012) . This leads to slower dissolution in the presence of electrolytes and, hence, a slower, more prolonged absorption. This approach was commercially applied many years ago to develop extended-release products and reduce the frequency of administration of drugs with short half-lives. In this study, 25 mg phenylephrine tannate was administered as a combination tablet containing 200 mg guaifenesin (Treatment A) and compared with 10 mg phenylephrine HCl (Treatment D) (Fig. 2a, Table 1 ). Both products provided the same dose of free-base phenylephrine, permitting a direct comparison of systemic exposure. Treatment A: phenylephrine tannate 25 mg, guaifenesin 200 mg; Treatment B: phenylephrine HCl 10 mg, acetaminophen 650 mg; Treatment C: phenylephrine HCl 10 mg after a high-fat meal; Treatment D: phenylephrine HCl 10 mg. Abbreviations: PE: unconjugated phenylephrine; PE-S: phenylephrine-sulfate; PE-G: phenylephrine-glucuronide; 3-HMA: 3-hydroxymandelic acid; SD: standard deviation.
Phenylephrine was absorbed more slowly from the tannate salt, showing a delayed median TMAX (0.63 h) and lower mean CMAX (926.0 pg/mL) compared with the HCl salt (0.33 h and 1052 pg/mL, respectively). The statistical analysis comparing the tannate to HCL salt in Table 2 found that the ratio of least-squares geometric means for CMAX was 94.11 with the confidence interval (72.09%, 122.86%) extending below the lower bound (80.00%) for equivalence. However, the ratio for AUC∞ was 118.37 with the confidence interval (107.39%, 130.46%) extending above the upper bound (125.00%), indicating about 20% more systemic exposure from the tannate salt form.
Although guaifenesin or other formulation factors may have contributed to the observed differences in phenylephrine pharmacokinetics between the tannate and HCl salt forms (i.e., delayed absorption, lower CMAX, and higher AUC∞), the pharmacokinetic profile in Fig. 2a does not support a long-acting product that is intended for dosing every 8-12 h. Mean phenylephrine plasma concentrations were similar from 2 to 5 h after administration for both salt forms. In addition, the terminal exponential t ½ was short and comparable (1.51 and 1.22 h), and more aligned with the dosing frequency of 10 mg phenylephrine HCl every 4 h.
Although the tannate salt of phenylephrine slowed absorption as expected by its mechanism of slowing dissolution, its use as an extended-release product with a lower dosing frequency does not appear justified. Indeed, since the time of this study, the US Food and Drug Administration, has reviewed publicly available scientific literature on pre-1962 prescription cough, cold, and allergy products, and those that contain tannate salts, including phenylephrine tannate, are not generally recognized as safe and effective (Guidance for FDA Staff and Industry, 2011) . Tannate complexes or salts of active ingredients may be useful for tastemasking, but these would require approval under new drug applications. (Rahman et al., 2012) .
Effect of acetaminophen on phenylephrine pharmacokinetics
Phenylephrine was rapidly absorbed when administered after fasting as either two combination tablets in Treatment B (10 mg phenylephrine HCl, 650 mg acetaminophen) or one tablet in Treatment D (10 mg phenylephrine HCl) with median TMAX of 0.42 and 33 h, respectively (Fig. 2b, Table 1 ). However, when combined with acetaminophen, mean phenylephrine CMAX was approximately 200% higher than when administered alone (2458 pg/mL versus 1053 pg/mL) and mean AUC∞ was approximately 50% higher (1246 pg h/mL versus 815.6 pg h/mL). The statistical analysis in Table 2 comparing phenylephrine exposure with and without acetaminophen found that the ratio of least-squares geometric means for CMAX was 232.44 with the confidence interval (178.06%, 303.44%) extending well above the upper bound for equivalence. Likewise, the ratio for AUC∞ was 161.55 with the confidence interval (146.57%, 178.05%) extending well above the upper bound.
This approximate doubling of CMAX was reported previously in four studies assessing the pharmacokinetics of 5 mg or 10 mg phenylephrine HCl administered with 500 mg or 1000 mg acetaminophen in combination tablets (Atkinson et al., 2014 (Atkinson et al., , 2015a . The drug-drug interaction was attributed to competition for presystemic sulfation, a metabolic pathway shared by both phenylephrine and acetaminophen. Although no changes in blood pressure were observed at phenylephrine plasma concentrations that correlated with a 20-mg phenylephrine dose in these studies (Atkinson et al., 2015a) , the potential safety implication of increased phenylephrine bioavailability was explored in a pharmacokinetic modeling and simulation analysis (Atkinson et al., 2015b) . Simulations using previously published data on blood pressure changes with administration of phenylephrine topical eye drops during ophthalmic surgery predicted an increase in mean diastolic and systolic pressure of 16 and 20 mmHg, respectively, for a 45-mg oral dose of phenylephrine HCl. However, in a crossover study in which healthy subjects received single oral doses of 10, 20, and 30 mg phenylephrine HCl or placebo, serial pulse, blood pressure, and electrocardiograms over 12 h were comparable, showing similar fluctuations and no, or minimal, effects (Gelotte and Zimmerman, 2015) .
Effect of food on phenylephrine pharmacokinetics
Following the standard high-fat breakfast, phenylephrine was absorbed more slowly from the 10-mg HCl tablet, showing a delayed median TMAX (0.50 h) and lower mean CMAX (591.2 pg/mL) compared with the fasted state (0.33 h and 1053 pg/mL, respectively) (Fig. 2c , Table 1 ). The statistical analysis comparing the fed to fasted states in Table 2 found that the ratio of least-squares geometric means for CMAX was 60.98 with the confidence interval (46.71%, 79.61%) extending well below the lower bound for equivalence. Mean total exposure (AUC∞ fed = 713.4 pg h/mL; AUC∞ fasted = 782.5 pg h/mL) was not affected by food, as the ratio of least-squares geometric means was 94.95 with the confidence interval (86.15%, 104.66%) falling within the equivalence range (80.00%, 125.00%).
Urine pharmacokinetic analysis
In urine, the percentages of dose across treatments excreted as phenylephrine-sulfate and 3-HMA were generally comparable with previously reported data for a 10-mg dose (46.6% and 25.3%, respectively, Gelotte and Zimmerman, 2015) . Likewise, the percentages excreted as unconjugated phenylephrine and phenylephrine-glucuronide were similarly negligible as previously reported (0.443% and 0.033%, respectively, Gelotte and Zimmerman, 2015) . Notably, the percent of the 10-mg phenylephrine dose excreted as phenylephrine sulfate when administered as the combination product in Treatment B was slightly lower (33.5%) than other treatments in this study (43.3%-49.6%, Table 3 ). These data support the premise that acetaminophen competes with presystemic sulfation during first-pass metabolism resulting in a lower fraction of the phenylephrine dose being excreted as phenylephrine sulfate. In this study, the amounts of sulfate conjugate excreted were estimated indirectly after sulfatase digestion of urine samples. Availability of validated assays to quantitate phenylephrine sulfate and another metabolite of phenylephrine, m-hydroxyphenylglycol-sulfate, directly would improve the precision of the urine metabolite data collected.
Safety
No serious or severe adverse event was reported, and no subject discontinued due to an adverse event. During the study, six of 20 subjects reported two moderate and seven mild adverse events. Two adverse events (nasal congestion and vomiting) were considered remotely related to phenylephrine tannate-guaifenesin in Treatment A. The remaining seven adverse events were considered unrelated to study drug: cough (2), nausea, dizziness, pharyngolaryngeal pain, nodule on extremity, and headache. No clinically relevant changes in vital signs or physical findings were observed.
Conclusion
Results of this exploratory study add to our understanding of the clinical pharmacology of phenylephrine and may provide preliminary data to design studies in the development of future phenylephrinecontaining products. For example, food was found to delay the absorption of phenylephrine, but not the total amount absorbed. Additionally, the finding that the combination product containing the tannate salt had similar terminal plasma concentrations as the reference product containing the HCl salt, and hence, should not be dosed less frequently, aligns with the regulatory action to remove prescription products containing phenylephrine tannate from the market. 
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